ImageneBio (NASDAQ:IMA) Upgraded by HC Wainwright to Strong-Buy Rating

ImageneBio (NASDAQ:IMA) was upgraded by stock analysts at HC Wainwright to a “strong-buy” rating in a research report issued on Friday,Zacks.com reports.

A number of other research analysts have also weighed in on IMA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research note on Monday, June 29th. Wedbush restated an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. Finally, Wall Street Zen cut shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $29.00.

ImageneBio Trading Down 1.8%

Shares of IMA opened at $5.51 on Friday. The stock has a market cap of $62.54 million, a P/E ratio of -1.20 and a beta of 0.76. ImageneBio has a 1 year low of $3.94 and a 1 year high of $14.34. The stock’s 50-day moving average price is $5.79 and its two-hundred day moving average price is $5.86.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.27. As a group, equities analysts forecast that ImageneBio will post -3.07 EPS for the current year.

Institutional Investors Weigh In On ImageneBio

A number of hedge funds and other institutional investors have recently bought and sold shares of IMA. Blue Owl Capital Holdings LP acquired a new stake in ImageneBio in the 2nd quarter valued at approximately $5,414,000. Deep Track Capital LP acquired a new position in ImageneBio during the 3rd quarter worth approximately $7,160,000. Cable Car Capital LP acquired a new position in ImageneBio during the 2nd quarter worth approximately $4,611,000. Trails Edge Capital Partners LP bought a new position in shares of ImageneBio during the 2nd quarter worth approximately $1,663,824,000. Finally, Vanguard Group Inc. bought a new position in shares of ImageneBio during the 3rd quarter worth approximately $1,902,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.